Elicio Therapeutics, Inc. (ELTX)
2.41
-0.09
(-3.60%)
USD |
NASDAQ |
Sep 04, 12:26
Elicio Therapeutics Research and Development Expense (TTM) : 23.51M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.51M |
| March 31, 2026 | 23.68M |
| December 31, 2025 | 24.70M |
| September 30, 2025 | 30.29M |
| June 30, 2025 | 32.44M |
| March 31, 2025 | 33.58M |
| December 31, 2024 | 33.34M |
| September 30, 2024 | 28.58M |
| June 30, 2024 | 28.71M |
| March 31, 2024 | 25.56M |
| December 31, 2023 | 23.45M |
| September 30, 2023 | 21.58M |
| Date | Value |
|---|---|
| June 30, 2023 | 18.81M |
| March 31, 2023 | 18.90M |
| December 31, 2022 | 25.16M |
| September 30, 2022 | 27.80M |
| June 30, 2022 | 36.57M |
| March 31, 2022 | 45.95M |
| December 31, 2021 | 48.61M |
| September 30, 2021 | 53.02M |
| June 30, 2021 | 45.84M |
| March 31, 2021 | 43.60M |
| December 31, 2020 | 38.88M |
| September 30, 2020 | 38.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Precigen, Inc. | 31.01M |
| Agenus, Inc. | 57.69M |
| Amgen, Inc. | 7.638B |
| Anika Therapeutics, Inc. | 27.45M |
| BioCryst Pharmaceuticals, Inc. | 195.46M |